1 / 15

Kawasaki Disease

Kawasaki Disease. Morning Report July 16 th , 2013. Epidemiology. Previously known as mucocutaneous lymph node syndrome Incidence is greatest in children in East Asia or are of Asian ancestry Boys more commonly affected than girls 80-90% of cases in children < 5 yo

marilu
Download Presentation

Kawasaki Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Kawasaki Disease Morning Report July 16th, 2013

  2. Epidemiology • Previously known as mucocutaneous lymph node syndrome • Incidence is greatest in children in East Asia or are of Asian ancestry • Boys more commonly affected than girls • 80-90% of cases in children < 5 yo • Most countries noted increase in cases since early 2000s • Risk factors for poor coronary artery outcomes: • Young age, especially < 6 months • Asian and Pacific Islander race • Hispanic ethnicity

  3. Pathogenesis • Unknown! • Infectious? • Seasonal peaks occurred in US and Japan w/ increased incidence in localized areaspossibletransmissable vector • Toxin-mediated? Rash can resemble erythrodermasimilar to TSS or SSSS and IVIG could work by binding toxin • Infection-triggered Inflammation • Many patients w/ KD have documented concomitant infections • Infectious agents could trigger an inflammatory cascade

  4. Clinical Manifestations • Diagnosis requires fever > 5 days and at least 4 of the following features: Conjunctivitis Rash Adenopathy Strawberry Tongue Hands/Feet and Burn

  5. Clinical Manifestations • Fever • Must be present ≥ 5 days • Most consistent manifestation • Minimally responsive to anti-pyretics • Remains > 38.5 during most of illness

  6. Clinical Manifestations • Conjunctivitis • Bilateral non-exudative • Present in >90% of patients • Mainly bulbar injection which spares the limbus • Can be associated w/ photophobia • Typically begins within days of the onset of fever • Anterior uveitis may also be seen on slit lamp exam

  7. Clinical Manifesations • Rash • Usually appears within 5 days of fever onset • Often starts as desquamation in perineal area and evolves into a diffuse, erythematous maculopapular rash • Morbilliform and targetoid rashes can also occur • Vesicular/bullous lesions are rare

  8. Clinical Manifestations • Adenopathy • Unilateral • Located in anterior cervical chain • Non-fluctuant and non-tender • Diameter should be > 1.5 cm • Cervical lymph node enlargement is least consistent feature

  9. Clinical Manifestations • Strawberry Tongue (Mucositis) • Cracked, red lips • Strawberry tongue (sloughing of filiform papillae and denuding of inflamed tissue) • Discrete oral lesions are NOT seen

  10. Clinical Manifestations • Hand/Feet Changes • Indurated edema of the dorsum of their hands and feet • Diffuse erythema of palms and soles • Characteristic periungual peeling from fingers and toes begins 2-3 weeks after the onset of fever • Generally the last manifestation to appear

  11. Other Manifestations • Arthritis • Up to 25% of patients • Large joints primarily involved • GI (61%) • Diarrhea • Vomiting • Abdominal Pain • Hydrops of the gallbladder • Irritability (50%) • Likely due to meningeal inflammation • Cough or Rhinorrhea (35%)

  12. Lab Findings • Elevated Neutrophil count w/ bandemia • Elevated ESR and CRP • Anemia (normocytic, normochromic) • Hypoalbuminemia • Thrombocytosis (after the 1st week of illness) • Sterile pyuria • Elevated serum transaminases (40%) • Abnormal plasma lipids • Pleocytosis of CSF • Echo: evaluate for coronary aneurysms, decreased LV functioning, pericardial effusions

  13. Management • Echo • Obtained at diagnosis, 1-2 weeks later, and 6 weeks post-discharge • IVIG • 2g/kg • Ideally, given within first 7 days of illness, and by day 10 (from 1st day of fever) • 15% will have persistent fever after 1stdoseresistant to IVIG • Controversial, but most are given another dose after day 10 if persistent fever • Aspirin • High dose (80-100 mg/kg/d): Anti-inflammatory, given until afebrile x 48h • Low dose (3-5mg/kg/d): Anti-thrombotic, given until echo results are normal after 6 weeks

  14. Prognosis • Relates entirely to extent of cardiac involvement • If IVIG given in time, incidence of coronary artery lesions is 5% • Aneurysms can regress to normal lumen diameter, but endothelial function is still impaired in these segments • Stenoses can developincreased risk of myocardial ischemia • Most children do well after single dose of IVIG • Mortality is < 0.5% • Highest risk is in the first year after onset of illness because of acute MI in patients with giant aneurysms

More Related